CompletedNot Applicable

Doxycycline for the Prevention of Spontaneous Bacterial Peritonitis

United States841 participantsStarted 2019-11-04

Plain-language summary

The utilization of doxycycline for SBP prophylaxis is a novel practice at MDMC. Therefore, an assessment of safety and efficacy is needed in order to generalize this practice. The publication of this study can potentially introduce a new alternative to guideline-directed therapies for secondary prevention of SBP. Doxycycline is non-inferior to guideline-directed therapies regarding safety and efficacy in primary and secondary prophylaxis for SBP.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients ≥ 18 year-old with refractory ascites who are candidates for SBP prophylaxis per clinician's decision * Patients diagnosed with cirrhosis based on clinical criteria * Patients with a diagnosis of SBP confirmed by paracentesis Exclusion Criteria: * Patients who have secondary peritonitis other than SBP * Patients who have a history of liver transplant prior to the initial episode of SBP * Patients with incomplete medical records

What they're measuring

Occurrence of reported SBP

Timeframe: July 2014 to July 2018

Trial details

NCT IDNCT04153604

SponsorMethodist Health System

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-08-07

View on ClinicalTrials.gov More Cirrhosis trials